Search Results

The IRMA Blood Analysis System is intended for professional use in those settings where direct measurement of blood such as blood gases (pCO2 and pO2), pH, Na , K , iCa BUN. CI'. and Hct. in whole blood are performed such as the clinical laboratory or the patient bedside.

The pH, pCO2, pO2 measurements, and their associated calculated values are used to assess acid-base status and state of oxygenation. Common causes of acid-base disturbances include: cardiopulmonary disease, metabolic abnormalities, drugs and poisons, and fluid imbalance.

The electrolyte measurements (Na . K . Cl) are used to assess hydrational status, aid in the diagnosis of respiratory and metabolic acid-balance, and prevention of cardiac arrhythmia. Common disease states which utilize these measurements for diagnosis are acid-base disturbances, dehydration, diarrhea, ketoacidosis, alcoholism and other toxicities.

The measurement of ionized calcium is used to assess disease states such as thyroid abnormalities, renal failure or transplant, and to monitor dialysis patients.

The measurement of blood urea nitrogen is used to monitor renal disease, dialysis --patients, and hyperalimentation.

The measurement of hematocrit is used to assess anemia, blood loss such as in an accident or during surgical procedures, and polycythemia.

With the addition of BUN and Cr, the IRMA Blood Analysis System will measure: blood gases (pCO2 and pO2), pH, sodium, potassium, ionized calcium, blood urea nitrogen, chloride, and hematocrit. The sensor arravs of the cartridge will also be packaged in various combinations.

The current IRMA Blood Analysis System comprises a system of an electronic instrument and disposable cartridges (single-use or multi-use) intended for the measurement of blood gases (pCO2 and pO2), pH, potassium, sodium, ionized calcium, and hematocrit in blood.

The new system will measure the above mentioned analytes plus blood urea nitrogen (BUN) and chloride (Cl) in blood on the single-use cartridge. Except for the addition of these two analytes and their associated changes, the system will remain the same as the current system.

The IRMA analyzer can use either battery or AC power. The system's operation utilizes a microprocessor which is controlled by internal electronics and diagnostics. The microprocessor controls the touch screen, analog electronics which collect the digital signals from the sensors and the controls the printer. The printer provides a hard copy of the measured and calculated values.

Samples are introduced via syringe or capillary injections with the IRMA Capillary Collection Device. The minimum sample volumes are 200uL from a syringe injection and 125uL from a Capillary Collection Device injection. Other capillary collection devices which require aspiration are not compatible with the system.

The cartridges utilize microelectrode technology for the measurement of the following blood analytes: pH, pCO2, pO2, sodium, potassium, ionized calcium, blood urea nitrogen, chloride, and hematocrit.

The principles of measurement are similar to traditional electrode methodologies for blood gas and electrolyte measurements. The pH, pCO2, Na*, K*, iCa**, BUN, and Cli utilize ion-selective potentiometric electrodes including a reference electrode. The pO2 electrode is an amperometric Clark electrode. The hematocrit sensor utilizes a conductivity electrode.

Here's a breakdown of the acceptance criteria and study information for the IRMA Blood Analysis System's BUN and Chloride sensors, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

Note: The acceptance criteria are "not explicitly stated" in numerical form within the provided text. They are implied by the statement "indicate substantial equivalence between Cl- and BUN sensors on the IRMA Blood Analysis System and the predicate devices" and the presentation of strong correlation coefficients.

2. Sample Size Used for the Test Set and Data Provenance

• Chloride (Cl-) Test Set Sample Size: n = 99
• BUN Test Set Sample Size: n = 97
• Data Provenance:
  • Country of Origin: Not explicitly stated, but the submission is to the US FDA and the company is based in Roseville, MN, USA.
  • Retrospective or Prospective: Not explicitly stated, but the description "split sample studies were conducted using whole blood samples measured by both the IRMA system and a reference method" and "heparinized whole blood samples were prepared by spiking with varying concentrations of electrolytes to allow testing throughout the reportable range" suggests a prospective study where samples were prepared and then tested on both systems.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications

• Number of Experts: The text states, "Testing was conducted by three laboratory personnel."
• Qualifications of Experts: Not explicitly stated beyond "laboratory personnel." No specific professional certifications (e.g., medical technologist) or years of experience are mentioned. The document notes that the IRMA system was previously cleared for use by non-laboratory personnel, and this submission's data does not include such personnel.

4. Adjudication Method for the Test Set

• Adjudication Method: Not explicitly described. The study appears to rely on direct comparison of the IRMA system's results against a reference method, rather than an adjudication process between multiple readers/interpretations. "The method of least squares was used to determine the best fit line."

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and Effect Size

• MRMC Study Done?: No, an MRMC comparative effectiveness study was not done. This study focuses on the analytical accuracy and precision of a diagnostic device (blood analyzer) compared to reference methods, not on human reader performance with or without AI assistance.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

• Standalone Performance Done?: Yes, the accuracy and precision data presented for Chloride and BUN represent the standalone performance of the IRMA Blood Analysis System's sensors, measuring the analytes in blood and aqueous samples. It's an instrument-based measurement, not an AI or human interpretation task.

7. The Type of Ground Truth Used

• Type of Ground Truth: Reference methods, specifically a Vitros Chemistry System DT6011 (for BUN) and a Buchler Digital Chloridometer (for Chloride) for accuracy studies. For precision, aqueous standards and control materials with known concentrations were used.

8. The Sample Size for the Training Set

• Training Set Sample Size: Not applicable. The IRMA Blood Analysis System is a medical device based on established electrochemical and enzymatic methodologies, not a machine learning or AI model that requires a "training set" in the traditional sense. Its "training" is in its engineering design, calibration, and manufacturing process.

9. How the Ground Truth for the Training Set Was Established

• How Ground Truth for Training Set Was Established: Not applicable, as this is not a machine learning device. The "ground truth" for its operation is inherent in the design and calibration using NIST traceable gases and salt standards, as described in the "Calibration" section.

Ask a specific question about this device

The IRMA Blood Analysis System is intended for professional use in those settings where blood analysis of blood gases (pCO2 and pO2), pH, Na+, K+, iCa++ and Hct in whole blood are performed such as the clinical laboratory or the patient bedside. The system may utilize either a single-use or a multi-use cartridge for these measurements.

The pH, pCO2, pO2 measurements, and their associated calculated values are used to assess acid-base status and state of oxygenation. Common causes of acid-base abnormalities, drugs and poisons, and fluid imbalance.

The electrolyte measurements (Na+, K+) are used to assess hydrational status, aid in the diagnosis of respiratory and metabolic acid-balance, and prevention of cardiac arrhythmia. Conditions which utilize these measurements for diagnosis are malnutrition, diarrhea, ketoacidosis, alcoholism and other toxicities.

The measurement of ionized calcium is used to assess disease states such as thyroid abnormalities, renal failure or transplant, and to monitor dialysis patients.

The measurement of hematocrit is used to assess anemia, blood loss such as in an accident or during surgical procedures, and polycythemia.

These indications for use of the IRMA Blood Analysis System which utilizes the multiuse cartridge are identical to those of the IRMA Blood Analysis System which utilizes the single-use cartridge. The System will now offer the user an option to choose which cartridge platform best fits their needs either the single-use or multi-use cartridge. Both platforms offer the following sensors: blood gases (pCO2 and pO2), pH, sodium, potassium, ionized calcium, and hematocrit. Similar to the single-use cartridge, the sensor arrays of the multi-use cartridge will also be packaged in various combinations.

Not Found

The provided document is a 510(k) clearance letter from the FDA for the IRMA® Blood Analysis System with an Optional Multi-Use Cartridge. It confirms that the device is substantially equivalent to legally marketed predicate devices.

However, the document does NOT contain information about:

• Specific acceptance criteria metrics (e.g., sensitivity, specificity, accuracy targets).
• Any study that proves the device meets acceptance criteria.
• Sample sizes for test sets or training sets.
• Data provenance.
• Number or qualifications of experts for ground truth establishment.
• Adjudication methods.
• Multi-reader multi-case (MRMC) comparative effectiveness studies.
• Standalone algorithm performance studies.
• The type of ground truth used (e.g., pathology, outcomes data).

The document is purely a regulatory clearance notice and details the device's intended use and indications for use. It states that the system measures blood gases (pCO2 and pO2), pH, Na+, K+, iCa++, and Hct in whole blood, either with a single-use or multi-use cartridge, in settings such as clinical laboratories or patient bedsides. The indications for use are for assessing acid-base status, hydration, electrolyte balance, cardiac arrhythmias, disease states related to calcium, anemia, and blood loss.

Ask a specific question about this device

The IRMA® Blood Analysis System is intended for professional use in those settings where direct measurement of blood such as blood gases (pCO2 and pO2), pH, Na+, K+, iCa++ and Hct in whole blood are performed such as the clinical laboratory or patient bedside, and The IRMA/Lifescan SureStep®Pro glucose module is intended for quantitative measurement of glucose in a sample of whole blood. It can be used in a clinical setting to measure glucose in arterial, venous, and capillary samples in both adults and neonates. It can also be used by lay persons for capillary blood glucose monitoring in the home.

Indications for Use:
The pH, pCO2, pO2 measurements, and their associated calculated values are used to assess acid-base status and state of oxygenation. Common causes of acid-base disturbances include cardiopulmonary disease, metabolic abnormalities, drugs and poisons, and fluid imbalance.

The electrolyte measurements (Na+ K+)are used to assess hydrational status, aid in the diagnosis of respiratory and metabolic acid-balance, and prevention of cardiac armythmia. Common disease states which utilize these measurements are acid-base disturbances, dehydration, diarrhea, ketoacidosis, alcoholism and other toxicities.

The measurement of ionized calcium is used to assess disease states such as thyroid abnormalities, renal failure or transplant, and to monitor dialysis patients.

The measurement of hematocrit is used to assess anemia, blood loss such as in an accident or during surgical procedures, and polycythemia.

The measurement of glucose on the module is used to monitor glucose levels in diabetic patients. It is not intended to be used for the diagnosis of diabetes.

These indications for use are identical to the predicate devices since the new system consists of an integration of the two predicate devices.

Not Found

This document is a 510(k) clearance letter for the Diametrics Medical IRMA Blood Analysis System, dated December 18, 1997. It primarily focuses on the regulatory approval and intended use of the device, rather than detailed performance study results or acceptance criteria.

Therefore, the requested information regarding acceptance criteria, study data, sample sizes, expert qualifications, adjudication methods, MRMC studies, standalone performance, and ground truth establishment for a device study is not present in the provided text.

The document states:

• Device Name: IRMA Blood Analysis System with Optional Lifescan SureStep®Pro Blood Glucose Module
• Intended Use: For professional use to directly measure blood gases (pCO2, pO2), pH, Na+, K+, iCa++, and Hct in whole blood in clinical laboratory or patient bedside settings. The glucose module is for quantitative measurement of glucose in whole blood for adults and neonates in clinical settings, and by laypersons for capillary blood glucose monitoring at home.
• Indications for Use: Details the clinical applications of the pH, pCO2, pO2, Na+, K+, ionized calcium, hematocrit, and glucose measurements.
• Substantial Equivalence: The FDA determined the device is substantially equivalent to predicate devices, indicating that the new system integrates two predicate devices with identical indications for use.

To answer your specific questions, a different type of document, such as a summary of safety and effectiveness, clinical study report, or internal validation report, would be required. This 510(k) clearance letter confirms regulatory approval based on equivalence but does not provide the detailed performance study data you're asking for.

Ask a specific question about this device